NO924614L - Siliaer neurotrof faktorreseptor - Google Patents

Siliaer neurotrof faktorreseptor

Info

Publication number
NO924614L
NO924614L NO92924614A NO924614A NO924614L NO 924614 L NO924614 L NO 924614L NO 92924614 A NO92924614 A NO 92924614A NO 924614 A NO924614 A NO 924614A NO 924614 L NO924614 L NO 924614L
Authority
NO
Norway
Prior art keywords
cntf
neurotrof
cilia
factor receptor
receptor
Prior art date
Application number
NO92924614A
Other languages
English (en)
Norwegian (no)
Other versions
NO924614D0 (no
Inventor
Samuel Davis
Stephen P Squinto
Mark E Furth
George D Yancopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/676,647 external-priority patent/US5426177A/en
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of NO924614D0 publication Critical patent/NO924614D0/no
Publication of NO924614L publication Critical patent/NO924614L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
NO92924614A 1990-06-01 1992-11-30 Siliaer neurotrof faktorreseptor NO924614L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53228590A 1990-06-01 1990-06-01
US07/676,647 US5426177A (en) 1990-06-01 1991-03-28 Ciliary neurotrophic factor receptor
US70067791A 1991-05-15 1991-05-15
PCT/US1991/003896 WO1991019009A1 (en) 1990-06-01 1991-06-03 The ciliary neurotrophic factor receptor

Publications (2)

Publication Number Publication Date
NO924614D0 NO924614D0 (no) 1992-11-30
NO924614L true NO924614L (no) 1993-01-21

Family

ID=27415086

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92924614A NO924614L (no) 1990-06-01 1992-11-30 Siliaer neurotrof faktorreseptor

Country Status (14)

Country Link
EP (1) EP0533846B1 (de)
JP (1) JP3266611B2 (de)
AT (1) ATE195341T1 (de)
AU (1) AU656732B2 (de)
CA (1) CA2084075C (de)
DE (1) DE69132361T2 (de)
FI (1) FI925457A0 (de)
HU (2) HUT63464A (de)
IE (1) IE911867A1 (de)
IL (1) IL98304A (de)
LV (1) LV10312B (de)
NO (1) NO924614L (de)
PT (1) PT97821A (de)
WO (1) WO1991019009A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169764A (en) * 1990-08-08 1992-12-08 Regeneron Pharmaceuticals, Inc. Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras
US5360740A (en) * 1992-07-02 1994-11-01 Regeneron Pharmaceuticals, Inc. Assay system for degenerative muscle disease
US6472178B1 (en) 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
AU6130094A (en) * 1993-01-29 1994-08-15 Regeneron Pharmaceuticals, Inc. Methods of treatment using ciliary neurotrophic factor
DE69410473T2 (de) * 1993-09-09 1998-10-22 Regeneron Pharma Testsystem unter verwendung des cntf-signaltransduktionsweges
DE4331297A1 (de) * 1993-09-15 1995-03-16 Henkel Kgaa Stückseifen
EP1365785A2 (de) * 2000-05-24 2003-12-03 Regeneron Pharmaceuticals, Inc. Verwendung von ciliary neurotrophic factor
US20200297868A1 (en) * 2016-12-14 2020-09-24 University Of Cincinnati Methods and compositions for the treatment of als
CN113607714B (zh) * 2021-10-08 2022-01-11 成都齐碳科技有限公司 分子膜成膜或表征器件、装置、方法以及生物芯片

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017375A (en) * 1982-11-24 1991-05-21 Baylor College Of Medicine Method to prepare a neurotrophic composition
US4923696A (en) * 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
US4997929A (en) * 1989-01-05 1991-03-05 Synergen, Inc. Purified ciliary neurotrophic factor
US5011914A (en) * 1989-01-05 1991-04-30 Collins Franklin D Purified ciliary neurotrophic factor
IE903130A1 (en) * 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor
HUT62033A (en) * 1990-03-14 1993-03-29 Fidia Spa Process for producing human ciliary body neuronotropic factor
IT1247150B (it) * 1991-01-21 1994-12-12 Fidia Spa Processo per la sintesi e la purificazione del fattore neuronotroficociliare umano (cntf) da escherichia coli.

Also Published As

Publication number Publication date
FI925457L (fi) 1992-11-30
IL98304A (en) 2008-08-07
JP3266611B2 (ja) 2002-03-18
DE69132361T2 (de) 2001-03-29
EP0533846A4 (de) 1994-04-27
LV10312A (lv) 1994-10-20
NO924614D0 (no) 1992-11-30
WO1991019009A1 (en) 1991-12-12
AU656732B2 (en) 1995-02-16
EP0533846A1 (de) 1993-03-31
ATE195341T1 (de) 2000-08-15
DE69132361D1 (de) 2000-09-14
HU211976A9 (en) 1996-01-29
CA2084075A1 (en) 1991-12-02
IL98304A0 (en) 1992-06-21
IE911867A1 (en) 1991-12-04
AU8233791A (en) 1991-12-31
FI925457A7 (fi) 1992-11-30
JPH06507062A (ja) 1994-08-11
CA2084075C (en) 2005-08-16
HUT63464A (en) 1993-08-30
LV10312B (en) 1995-10-20
FI925457A0 (fi) 1992-11-30
PT97821A (pt) 1992-02-28
EP0533846B1 (de) 2000-08-09
HU9203772D0 (en) 1993-03-29

Similar Documents

Publication Publication Date Title
CA2275504A1 (en) Pharmacogenetic methods for use in the treatment of nervous system diseases
DK0784703T3 (da) Lamininkæder: Diagnostisk og terapeutisk anvendelse
ATE360808T1 (de) Unabhängiges gerät zur extraktion, amplifikation und nachweis von nukleinsäuren
CA2241111A1 (en) Process for the microbial production of amino acids by boosted activity of export carriers
ATE79261T1 (de) Verfahren zur behandlung von magen-darmstoerungen.
ATE185083T1 (de) Vorrichtung zur verabreichung von medikamenten und genen durch elektroporation
EP1361229A3 (de) Verwendung von Tyrosine Kinase (PYK2) zur Produktion von Antikörper
ATE241351T1 (de) Isobutylgaba und dessen derivate zur schmerzbehandlung
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
NO924614L (no) Siliaer neurotrof faktorreseptor
ES2187648T3 (es) Metodo para la administracion de farmacos para terapia genica.
ATE85707T1 (de) Entwicklungsverfahren fuer arzneimittel zur behandlung von stoerungen.
DE69836679D1 (de) Peptide zur behandlung des systemischen lupus erythematosus
EP0870036A4 (de) Synthetische säugetier alpha-n-aectylglukosaminidase und dafür kodierende genetische sequenzen
EP1471143A4 (de) Gegenüber einer rheumatoiden arthritis-erkrankung sensitives gen, sein protein, verfahren und kit zur beurteilung des ausbruchs von rheumatoider arthritis unter verwendung desselben sowie verfahren und arzneistoffe zur behandlung rheumatoider arthritis
UA19794A (uk) Спосіб моделюваhhя виразки шлуhку
Rasmussen SPECIAL CONDITIONS OF TENNESSEE PAROLE: A STUDY OF COMPLIANCE BEHAVIOR AND RECIDIVISM.
IT8622049A0 (it) Metodo per la determinazione dell'attivita' biologica della proteina c nel plasma umano, e relativi reagenti.
CA2201865A1 (en) Laminin chains: diagnostic and therapeutic use
IT210949Z2 (it) Sistema di identificazione positiva di pazienti in campioni per analisi mediche.
ATE94558T1 (de) Sialosylcholesterol, verfahren zu dessen herstellung und arzneimittel zur behandlung von krankheiten des nervensystems.
ATE38467T1 (de) Verfahren zur stimulation des menschlichen vestibularapparates und vorrichtung hierfuer.